Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a...

Area of Science:

• Genomics
• Molecular Biology
• Clinical Diagnostics

Background:

• Next-generation sequencing (NGS) offers potential for targeted DNA sequencing but faces challenges in clinical throughput, cost, and accuracy.
• Accurate mutation detection in genes like BRCA1 and BRCA2 is crucial for genetic disorder screening and patient management.

Purpose of the Study:

• To evaluate a PCR-based, multiplexed NGS workflow for targeted DNA sequencing of BRCA1 and BRCA2 genes.
• To assess the sensitivity, specificity, and scalability of SOLiD 4 and Ion Torrent PGM platforms for clinical mutation detection.

Main Methods:

• Targeted sequencing of BRCA1 and BRCA2 genes using SOLiD 4 (n=24) and Ion Torrent PGM (n=20) platforms.
• Comparison of NGS data against Sanger sequencing for mutation detection.
• Evaluation of DNA input requirements and sample types (peripheral blood vs. buccal wash).

Main Results:

• High overall sensitivity achieved: 97.8% for SOLiD and 98.9% for PGM.
• SOLiD platform demonstrated 100.0% specificity; PGM correctly identified all indels but had 68 false positives.
• Equimolar amplicon normalization was not required; low DNA input (325 ng) yielded comparable results.

Conclusions:

• The evaluated NGS workflow is accurate, sensitive, and scalable for BRCA mutation screening.
• This approach can potentially reduce BRCA testing costs to under $200 per patient.
• The method is easily integrated into existing workflows for broader clinical application in genetic disorder screening.